PeptideForward
Home / Peptides / PT-141
Longevity & Wellness

PT-141: uses, research, and availability

Bremelanotide (Vyleesi)

An FDA-approved peptide used for a specific sexual-health indication, taken on demand under provider guidance.

Class: Melanocortin receptor agonist Common use: Sexual health Route: Prescription Reviewed: May 2026
✅ Available now: PT-141 is an FDA-approved prescription medication. A licensed provider can prescribe it today for patients who meet clinical criteria. It does not depend on the 2026 peptide review.

What is PT-141?

PT-141, known generically as bremelanotide and marketed as Vyleesi, is an FDA-approved peptide. It is approved to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

Per its FDA-approved labeling, it is used on an as-needed basis ahead of anticipated activity rather than on a daily schedule, as directed by a prescriber.

How it is thought to work

PT-141 acts on melanocortin receptors in the nervous system that are involved in sexual response. This is a different pathway from blood-flow-based treatments, which work on the vascular system.

What the research shows

Approval was based on randomized trials in the indicated population that measured changes in sexual desire and related distress. Evidence outside the approved use is limited.

Our editorial standard

We summarize published research and do not make therapeutic promises. A licensed provider can evaluate whether any therapy is appropriate for you. Treat any source promising guaranteed results with skepticism.

Approved uses

  • The approved sexual-health indication in eligible patients
  • On-demand rather than daily dosing
  • Studied for desire and arousal pathways

PT-141 (bremelanotide) is FDA-approved and available now by prescription for its approved use. It does not depend on the 2026 peptide review.

How to access PT-141 legitimately

A licensed provider reviews your history to determine whether the approved indication applies and, if appropriate, prescribes the product through a licensed pharmacy.

PeptideForward can match you with vetted telehealth providers who handle these therapies through legitimate channels. The eligibility check takes about five minutes and there is no cost to see if you are a candidate.

Frequently asked questions

How is PT-141 used? It is FDA-approved (as Vyleesi) and used on an as-needed basis rather than as a daily medication. A licensed provider determines whether it is appropriate for you and directs how it should be used per its approved labeling.

Is it available now? Yes, for its approved use, prescribed by a licensed provider.

Does PeptideForward sell it? No. We connect you with licensed providers only.

Stay informed

Get 2026 peptide updates

One email when the FDA advisory committee decides, plus plain-language updates as access evolves. No spam.